TECOM-INVESTMENTS
In support of His Highness Sheikh Mohammed Bin Rashid Al Maktoum, Vice President of the UAE and Ruler and Prime Minister of Dubai’s vision to transform Dubai into an innovation-driven economy, TECOM Investments has today announced a new strategy that includes the development of innovation complexes, creative spaces, technology laboratories and smart buildings, as well as the launch of new business incubators and the establishment of a dedicated start up fund and competition to stimulate innovation. The new start-up fund and competition will be launched by Q2 2015.
The combined total investment allocated towards TECOM Investments’ new innovation focused initiatives is AED 4.5 billion, which will fund the development of infrastructure for d3’s Creative Community, Dubai Internet City’s Innovation Hub, incubator and creative spaces in all of the company’s communities, and expected to increase the workforce located in its business communities from 70,000 to 100,000; grow its business partner base from 4,500 to 10,000; and provide an additional 10 million sq. ft. of commercial office space in the coming 10 years.
To further drive innovation in Dubai, the company is also proud to reveal further detail for two major new projects: Dubai Internet City’s Innovation Hub and Dubai Design District’s (d3) Creative Community .
Dubai Internet City’s Innovation Hub will be a thriving 1.6 million sq. ft. business development located in the heart of Dubai Internet City, Dubai Media City and Dubai Knowledge Village, offering companies of all sizes in the technology, new media, smart education and sciences industries world class facilities and services, state-of-the-art infrastructure and a vibrant working environment. Phase one will be delivered in Q1 2017 and this initiative will further strengthen Dubai’s existing position as a strategic business destination, and drive the Emirate’s transition into a leading global innovation-led economy.
The d3 Creative Community will cover a total area of 1 million sq. ft. within Dubai Design District, and will act as an incubator for emerging local designers and artists, as well as providing a natural home for art galleries and studios looking to engage directly with the region. The Creative Community is expected to evolve organically, with adaptability providing one of its key attributes, enabling year round use of the built environment to cater for an active place management programme and flexible working spaces allowing businesses to grow and develop. Phase One of the development will be delivered in 2016.
Commenting, Dr Amina Al Rustamani, Group CEO of TECOM Investments, said: “TECOM Investments is a committed partner in the Government’s efforts to transform Dubai into an innovation-driven economy. We see our role as enabling businesses and creative people to operate efficiently and effectively, but we are also seeking to actively engage, foster, and nurture talent and creative industries in order for them to have a positive impact on the UAE economy.”
*Source: ME NewsWire
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20141102005026/en/
Contact:
For TECOM Investments
Alexa Hooft Graafland, +971-55-559-7404
AHooftGraafland@bell-pottinger.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
TreeFrog Therapeutics Secures €30 Million From European Investment Bank (EIB) Marking a Significant Milestone in the Company’s Journey to Accelerate the Field of Cell Therapy27.5.2025 13:15:00 CEST | Press release
€30 million financing with mix of dilutive and venture debt financingFunds to advance Parkinson’s disease cell therapy program to the clinic and further develop their internal pipeline of cell therapiesDeal benefits from guarantee under European Commission’s Invest EU program TreeFrog Therapeutics, a French biotech specializing in cell therapy has secured a €30 million financing from the European Investment Bank (EIB). The financing will support the advancement of their lead cell therapy program in Parkinson’s Disease to the clinic. Funds will also be used to reinforce their internal pipeline in other disease areas with large unmet needs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250527015423/en/ Vice-President Ambroise Fayolle, EIB and Frederic Desdouits, CEO TreeFrog Therapeutics sign financing of €30million to accelerate cell therapy programs. Regenerative medicine holds immense potential to revolutionize healthcare
ASCO 2025: REVEAL GENOMICS Unveils New HER2DX Data From 800+ Patients27.5.2025 13:03:00 CEST | Press release
HER2DX analysis includes data from over 800 patients across four studies in the neoadjuvant (CompassHER2 pCR, BionHER), adjuvant (RESPECT) and metastatic (DFCI) settings.In neoadjuvant trials, HER2DX identified HER2-positive tumors more likely to respond to single taxane and dual HER2 blockade, and significantly contributed to predicting which patients would have a pathologic complete response (pCR) when added to clinical factors.In the adjuvant RESPECT study, HER2DX delivered robust prognostic information and predicted chemotherapy benefit in older adults (aged 70–80 years) with HER2-positive early breast cancer.In the metastatic setting, HER2DX ERBB2 signature score was significantly associated with survival outcomes following trastuzumab deruxtecan monotherapy. REVEAL GENOMICS, S.L., a biotechnology company advancing precision oncology through biomarker innovation, today announced the presentation of four independent studies at the 2025 ASCO Annual Meeting. The studies, involving mo
CISOs Increasingly Rely on AI to Navigate Cost Pressures and Enhance Resilience: Wipro Report27.5.2025 12:30:00 CEST | Press release
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading technology services and consulting company, today released its "State of Cybersecurity Report 2025." The report underscores the growing importance of integrating AI into cybersecurity operations at a time of mounting cost pressures and increasingly sophisticated cyber threats. The report surveyed over 100 global cybersecurity leaders and consultants and found that AI-driven automation and cost optimization were among the main cybersecurity priorities for organizations. In fact, 30 percent of respondents state that investing in AI automation to bolster cybersecurity operations and reduce costs is a top priority. Other strategies used by CISOs to optimize costs include tools rationalization (26 percent), security and risk management process optimization (23 percent) and operating model simplification (20 percent). The report also highlights the growing role of AI in managing cyber threats and how investing in advanced AI-drive
BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Nasopharyngeal Cancer27.5.2025 12:00:00 CEST | Press release
Positive opinion for TEVIMBRA in combination with chemotherapy as a first-line treatment of nasopharyngeal cancer (NPC) based on results of RATIONALE-309 study demonstrating statistically significant improvement in progression-free survival BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending approval of TEVIMBRA® (tislelizumab), in combination with gemcitabine and cisplatin, for the first-line treatment of adult patients with recurrent, not amenable to curative surgery or radiotherapy, or metastatic NPC. “Chemotherapy has been the standard treatment for metastatic NPC; however, distant metastasis continues to be a significant cause of treatment failure and death, making new treatment options essential,” said Prof. Lisa Licitra, Chief of Head and Neck Cancer M
RHEACELL and AOP Health: Strategic Partnership to Deliver Breakthrough Therapies for the “Butterfly Children’s Disease” and Chronic Venous Wounds27.5.2025 11:40:00 CEST | Press release
Partnership aims to provide patients with high unmet medical needs access to innovative cell therapies RHEACELL, a German biotech company specialized in the development of stem cell therapies, and AOP Health, a Europe-based leader in integrated therapies for rare diseases and in intensive care, are forming a strategic alliance. This partnership marks a crucial step toward making breakthrough therapies available to patients with high unmet medical needs – particularly those affected by Epidermolysis bullosa (EB or “butterfly children’s disease”) and chronic venous wounds. Both conditions currently have limited treatment options, severely impacting the lives of patients and their families.Two novel therapies from RHEACELL’s pipeline are currently in Phase 3 clinical development. Combining RHEACELL’s cutting-edge R&D capabilities with AOP Health’s proven expertise in bringing rare disease therapies to patients in Europe, this partnership underscores both companies’ strong commitment to ad
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum